The SELECT trial is venturing into using semaglutide for patients with atherosclerotic cardiovascular disease (ASCVD) and obesity, suggesting a broader role for GLP1-RAs beyond diabetes management, extending into cardiovascular prevention [120,121]. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.